Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.56 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.56 |
| ▸ | RNASEL | Q05823 | 3/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30665600 | 1.00 | POLB (0.59) | POLBENPP1P2RY1RNASELP2RY2 | |
| SCHEMBL31606440 | 1.00 | POLB (0.59) | POLBENPP1P2RY1RNASELP2RY2 | |
| SCHEMBL29420330 | 1.00 | POLB (0.59) | POLBENPP1P2RY1RNASELP2RY2 | |
| SCHEMBL29540129 | 1.00 | POLB (0.59) | POLBENPP1P2RY1RNASELP2RY2 | |
| SCHEMBL16979764 | 1.00 | POLB (0.59) | POLBENPP1P2RY1RNASELP2RY2 | |
| SCHEMBL30839331 | 0.94 | P2RY2 (0.57) | POLBENPP1P2RY1RNASELP2RY2 | |
| SCHEMBL23140717 | 0.92 | RNASEL (0.54) | P2RY1RNASELP2RY2 | |
| SCHEMBL23157150 | 0.92 | RNASEL (0.54) | P2RY1RNASELP2RY2 | |
| SCHEMBL23140716 | 0.92 | RNASEL (0.54) | P2RY1RNASELP2RY2 | |
| SCHEMBL30632043 | 0.91 | DTYMK (0.66) | POLBENPP1P2RY1RNASELP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016118877-A1 | RIBOSOME-MEDIATED INCORPORATION OF PEPTIDES AND PEPTIDOMIMETICS | ARIZON BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2016-07-28 | — | — | WO | disclosed |
| US-9315537-B2 | Multiple orthogonal labelling of oligonucleotides | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-04-19 | — | — | US | disclosed |
| US-20150218203-A1 | MULTIPLE ORTHOGONAL LABELLING OF OLIGONUCLEOTIDES | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218203-A1 | MULTIPLE ORTHOGONAL LABELLING OF OLIGONUCLEOTIDES | RTCB, ADAR, POLN | POLB 54/4885ENPP1 1207/4885P2RY1 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.